LGG clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
FORE8394 in Participants With Cancer Harboring BRAF Alterations
open to eligible people ages 10 years and up
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
at UCLA UCSF
Our lead scientists for LGG research studies include Noah C. Federman, MD.
Last updated: